ARTICLE | Company News
Evec, Astellas deal
September 12, 2011 7:00 AM UTC
Evec granted Astellas exclusive, worldwide rights to develop and commercialize one of Evec's preclinical antibodies against infectious diseases. Evec will receive ¥600 million ($7.8 million) up front ...